The Valley Desk

NCT04636814 · Interventional trial

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

Overall registry status Terminated

Phase 3

Conditions Chronic Obstructive Pulmonary Disease

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov